ArticleMolecular imaging and biology2016
In Vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody.
Article in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment.Molecular diversity · 2024Article
- Metal and Metal Oxides Nanoparticles and Nanosystems in Anticancer and Antiviral Theragnostic Agents.Pharmaceutics · 2023Review
- Application of Nanoparticles in the Diagnosis of Gastrointestinal Diseases: A Complete Future Perspective.International journal of nanomedicine · 2023Review
- Iron Oxide Nanoparticle-Based Hyperthermia as a Treatment Option in Various Gastrointestinal Malignancies.Nanomaterials (Basel, Switzerland) · 2021Review
- Applications of Nanoparticle-Antibody Conjugates in Immunoassays and Tumor Imaging.The AAPS journal · 2021Review
- Magnetic Nanoparticles as MRI Contrast Agents.Topics in current chemistry (Cham) · 2020Review
- The role of MRI in the diagnosis and treatment of gastric cancer.Diagnostic and interventional radiology (Ankara, Turkey) · 2020Review
- Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency.Cancers · 2019Review
- Targeted Fe-doped silica nanoparticles as a novel ultrasound-magnetic resonance dual-mode imaging contrast agent for HER2-positive breast cancer.International journal of nanomedicine · 2019Article
- Article
- Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes.Journal of nanobiotechnology · 2018Article
- Experimental imaging in orthotopic renal cell carcinoma xenograft models: comparative evaluation of high-resolution 3D ultrasonography, in-vivo micro-CT and 9.4T MRI.Scientific reports · 2017Article
- Radioiodination of BODIPY and its application to a nuclear and optical dual functional labeling agent for proteins and peptides.Scientific reports · 2017Article
- Nanobubble Contrast Enhanced Ultrasound Imaging: A Review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe feasibility of iron oxide nanoparticles (IONPs) conjugated with anti-epidermal growth factor receptor 2 (HER2) single-chain antibody (scFv-IONPs) as novel HER2-targeted magnetic resonance (MR) contrast agents was investigated. PROCEDURES: The scFv-IONPs were prepared and identified. For in vitro MRI, NCI-N87 (HER2 high expression) and SUIT2 (low expression) cells were incubated with scFv-IONPs. For in vivo MRI, NCI-N87 and SUIT2 tumor-bearing mice were intravenously injected with scFv-IONPs and imaged before and 24 h post-injection.
resultsThe scFv-IONPs demonstrated high transverse relaxivity (296.3 s
conclusionsThe scFv-IONPs enabled HER2-specific tumor MR imaging, suggesting the potential of scFv-IONPs as a robust HER2-targeted MR contrast agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.